Analogously to what we have recently published for conglobatin A, elaiophylin may have a high efficacy in KRAS mutant cancers with high HIF1α and Gal3 levels, which is particularly the case in pancreatic cancer [15]. The gene discussed is KRAS; the disease is cancer.